Sun to stop selling cancer drug Oxaliplatin in US from July

Sun Pharmaceutical Industries today said it will stop selling generic Oxaliplatin, a cancer treatment drug, in the US after June 30, following an order by a New Jersey court.

“The US District Court of New Jersey denied Sun Pharma’s motion to suspend the court’s order dated April 22, which entered a consent judgment and order having the effect of enjoining Sun Pharma from selling a generic Oxaliplatin product,” the Mumbai-based company said in a statement. Accordingly, Sun Pharma will stop selling the product after June 30, it added.

Sun Pharma had appealed the court order and intends to litigate the matter before the United States Court of Appeals for the Federal Circuit, it added.

 

The company asserted that the grounds for appeal are strong and plans to contest the entry of the consent judgment and order vigorously.

“On receipt of a favourable judgment from the appellate court, Sun plans to re-initiate the sales of the product,” the statement added.